Clinical Presentation of Inflammatory Myopathies

Introduction to Inflammatory Myopathies

• The American College of Rheumatology suggests that inflammatory myopathies are characterized by proximal muscle weakness, elevated muscle enzymes, and variable extramuscular manifestations, including skin rash, interstitial lung disease, dysphagia, and cardiac involvement 1, 2

Muscular Manifestations

• The European League Against Rheumatism notes that patients with inflammatory myopathies typically present with symmetric proximal muscle weakness, making it difficult to rise from a chair, climb stairs, lift objects overhead, and comb their hair 1, 2
• The American College of Rheumatology recommends considering a diagnosis of inflammatory myopathy in patients with progressive muscle weakness developing over weeks to months, particularly in dermatomyositis and polymyositis 1

Laboratory Findings

• Elevated creatine kinase (CK) levels are typically seen in dermatomyositis and polymyositis, according to the American College of Rheumatology 1, 2
• Abnormal electromyography (EMG) findings, including short-duration, low-amplitude, polyphasic motor unit potentials and increased spontaneous activity, are characteristic of inflammatory myopathies, as noted by the European Federation of Neurological Societies 1, 3

Specific Subtypes and Their Distinctive Presentations

• Dermatomyositis is characterized by pathognomonic skin features, which may precede or accompany muscle weakness, including a photosensitive erythematous rash, Gottron's papules, heliotrope rash, and periungual telangiectasias, as described by the American Academy of Dermatology 1, 3
• Polymyositis presents with symmetric proximal muscle weakness without skin manifestations, and a distinctive immunohistopathological phenotype, with CD8+ T cells invading non-necrotic muscle fibers, according to the European League Against Rheumatism 2, 4

Extramuscular Manifestations

• Interstitial lung disease is a common extramuscular manifestation, particularly in patients with antisynthetase syndrome, as noted by the American Thoracic Society 1, 5, 3
• Dysphagia is a prominent feature in some patients, particularly those with inclusion body myositis, and may lead to the need for feeding tubes or recurrent aspiration pneumonia, according to the American Gastroenterological Association 5, 6, 7, 8

Cardiac Involvement

• Arrhythmias, including asymptomatic tachycardia, and conduction abnormalities may occur, as described by the American Heart Association 5, 6, 7, 8
• Diastolic dysfunction is visible on echocardiography, and myocarditis, although not typical, may be found on autopsy, according to the European Society of Cardiology 5, 6, 7, 8

Treatment

• The American College of Rheumatology recommends initiating high-dose corticosteroids concurrently with a steroid-sparing agent, such as methotrexate, azathioprine, or mycophenolate mofetil, followed by gradual reduction of corticosteroids in patients with non-severe disease 1, 2, 3
• In patients with severe or refractory disease, the use of high-dose methylprednisolone, intravenous immunoglobulin, cyclophosphamide, rituximab, or cyclosporine may be considered, as noted by the European League Against Rheumatism 1, 2, 3

Anticuerpos Específicos de Miositis en Miopatía Inflamatoria

Características Clínicas y Pronóstico

• Los anticuerpos anti-sintetasa, que incluyen anti-Jo-1, anti-PL-7, anti-PL-12, anti-OJ, anti-EJ, anti-KS, anti-Ha y anti-Zo, definen el síndrome antisintetasa y predicen manifestaciones extramusculares específicas, como miositis con debilidad muscular proximal simétrica, enfermedad pulmonar intersticial, artritis, fenómeno de Raynaud, manos de mecánico y fiebre, según la Mayo Clinic Proceedings 9, 10
• La presencia de anticuerpos anti-Jo-1 se encuentra en aproximadamente 20% de los pacientes adultos con miopatía inflamatoria idiopática, mientras que anti-PL-7 y anti-PL-12 se encuentran en menos de 5% cada uno, según la Mayo Clinic Proceedings 9, 10

Otros Anticuerpos Específicos de Miositis

• El anticuerpo anti-Mi-2 indica dermatomiositis clásica con manifestaciones cutáneas características, como pápulas de Gottron, signo del chal y eritema en heliotropo, y se encuentra en menos de 10% de los adultos y 4-10% de los pacientes con dermatomiositis juvenil, según la Mayo Clinic Proceedings 9, 10
• El anticuerpo anti-SRP se asocia con miopatía necrotizante de inicio agudo y miocardiopatía dilatada, y se encuentra en aproximadamente 5-10% de los adultos, según la Mayo Clinic Proceedings 9, 10
• El anticuerpo anti-p155/140 (TIF1-γ) se asocia fuertemente con malignidad en adultos, pero no en niños, según la Mayo Clinic Proceedings 9, 10

Implicaciones Clínicas y Recomendaciones

• La evaluación pulmonar inmediata con tomografía de alta resolución y pruebas de función pulmonar es crucial en pacientes con anticuerpos anti-sintetasa positivos, según la Mayo Clinic Proceedings 9
• La evaluación cardíaca completa, incluyendo troponina, electrocardiograma y ecocardiograma, es necesaria en pacientes con anticuerpos anti-SRP o anti-HMG-CoA reductasa positivos, según la Mayo Clinic Proceedings 9 y Annals of the Rheumatic Diseases 11
• La búsqueda exhaustiva de malignidad es crucial en adultos con anticuerpos anti-p155/140 positivos, según la Mayo Clinic Proceedings 9
• El monitoreo estrecho de la función pulmonar es necesario en pacientes con anticuerpos anti-MDA5 positivos, según la Mayo Clinic Proceedings 9

Limitaciones y Recomendaciones para la Práctica Clínica

• Los criterios de clasificación EULAR/ACR 2017 solo incluyeron cinco anticuerpos específicos de miositis debido a la falta de datos sobre otros anticuerpos más recientemente identificados, según Annals of the Rheumatic Diseases 12, 13
• Se recomienda solicitar un panel completo de anticuerpos específicos de miositis en todo paciente con sospecha de miopatía inflamatoria, ya que aproximadamente 80% de los pacientes tendrán al menos un anticuerpo detectable, lo que determinará el pronóstico, las manifestaciones extramusculares a vigilar y la agresividad del tratamiento requerido, según la literatura disponible 9, 10, 11, 12, 13

Anti‑Mi‑2 Positive Dermatomyositis: Evidence‑Based Guideline Summary

Diagnostic and Prognostic Significance

• A positive anti‑Mi‑2 antibody identifies a classic dermatomyositis phenotype with prominent skin involvement, a high likelihood of good response to therapy, a low risk of associated malignancy, and minimal interstitial lung disease. 14

• Anti‑Mi‑2 antibodies target a nuclear helicase that regulates transcription, thereby defining a distinct clinical subset of dermatomyositis. 14

Characteristic Clinical Features

• Heliotrope rash with periorbital edema is a hallmark cutaneous manifestation in patients who are anti‑Mi‑2 positive. 14

• The “V‑sign” (erythema over the anterior chest) is frequently observed in this antibody‑positive group. 14

• Ultraviolet light exposure may act as a trigger for disease onset in individuals with anti‑Mi‑2 antibodies. 14

Laboratory Findings

• Serum creatine kinase (CK) levels are typically elevated in anti‑Mi‑2 positive dermatomyositis, reflecting muscle injury. 14

Monitoring Treatment Response

• The American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2016 Total Improvement Score (0–100) incorporates Manual Muscle Testing‑8 as a core measure for assessing therapeutic response. 15

• Moderate improvement is defined as a ≥ 40‑point increase on the Total Improvement Score (sensitivity 90 %, specificity 96 %). 15

• Major improvement is defined as a ≥ 60‑point increase on the Total Improvement Score (sensitivity 90 %, specificity 96 %). 15